- Commission steps up research funding with €120 million for 11 new projects to tackle the virus and its variants
- “Agreement between BioNTech and Pfizer and Biovac to produce 100 million COVID-19 vaccines in South Africa is great news for Africa”, says Commission President von der Leyen
- Over 3 million vaccine doses shared via the EU Civil Protection Mechanism
- EMA starts rolling review of COVID-19 vaccine Vidprevtyn
- Get your vaccination information from public health authorities
Figures on vaccination
- 515.8 million doses delivered in the EU
- 436.6 million doses administered in the EU
- 68.4 %of the adult EU population received at least one dose
Last updated: 22 July 2021. Source: Vaccines producers and ECDC data
EU reaches the milestone of vaccine deliveries to vaccinate 70% of adult EU citizens
“We have delivered enough vaccines to Member States to be in a position to vaccinate fully at least 70% of EU adults still this month”, said Commission President Ursula von der Leyen as the EU marked a new milestone in the vaccination campaign on 11 July. She stressed however COVID-19 was not yet defeated, and that the EU was prepared to deliver more vaccines, including against new variants.
Information about vaccination in the EU
Securing doses of future vaccines
The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 6 promising vaccine developers, securing a portfolio of up to 4.4 billion doses.
Deliveries of vaccine doses to European Union countries have increased steadily since December. Vaccination gathers pace across the European Union.
The Commission has so far given 4 conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca and Janssen Pharmaceutica NV following EMA positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the European Medicines Agency (EMA).
The Commission is working closely with the industry to step up vaccine manufacturing capacity in the EU.
At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce on a large-scale vaccines effective against those variants.
This is why the European Commission has launched the HERA Incubator. It will bring together science, industry and public authorities, to speed up work and leverage all available resources to enable Europe to respond to this threat.
- up to 4.4 billion doses
Type of vaccine
Number of doses
(needed per person)
Number of doses
|BioNTech and Pfizer||mRNA||2 doses||2.4 billion*||Approved|
|Moderna||mRNA||2 doses||460 million||Approved|
|CureVac||mRNA||2 doses||405 million||Development ongoing|
|AstraZeneca||adenovirus||2 doses||400 million||Approved|
|Johnson & Johnson/Janssen Pharmaceuticals||adenovirus||1 dose||400 million||Approved|
|Sanofi-GSK||protein||2 doses||300 million||Development ongoing|
*option to purchase 900 million doses
The Commission has also concluded exploratory talks with
- Novavax with a view to purchasing up to 200 million doses, and
- Valneva with a view to purchase up to 60 million doses.
The European Medicines Agency publishes safety updates for the COVID-19 vaccines authorised in the EU. EMA releases a monthly update for each authorised COVID-19 vaccine.
The safety updates summarise the data that have become available since the vaccine's authorisation. They also indicate whether any safety information requires further investigation.
For more information, visit the EMA webpage.
Check the facts
Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).
You can also help by not sharing unverified information that comes from dubious sources.
The EU vaccine strategy
With the EU Vaccines Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.
Interview about vaccination with Ms Marie-Francoise Fuchs
How do vaccines work?